billS1630Event Tuesday, May 6, 2025Analyzed

MOMS Act

Neutral
Impact1/10

Summary

The MOMS Act (S.1630) is an early-stage bill referred to committee with no authorized funding amount. It creates a procedural requirement for HHS to build a pregnancy.gov website. There is no near-term market impact. Recent declines in $ACN and $IBM are driven by broader tech weakness, not this legislation.

See which stocks are affected

Key takeaways, market implications, full AI analysis, and connected signals are available to HillSignal members.

Already have an account? Log in

Key Takeaways

  • 1.The MOMS Act is a procedural bill with zero authorized funding and no near-term market impact.
  • 2.No public companies are directly affected; any potential IT contracting is purely hypothetical and immaterial.
  • 3.Recent stock declines in $ACN and $IBM are driven by broad market tech weakness, not this legislation.

Market Implications

No market implications from this bill. Investors should watch broader tech sector trends for $ACN and $IBM performance. $ACN's 52-week low of $173.67 is nearby, while $IBM is already near its low of $220.72. The 30-day declines of -10.47% and -5.91% respectively reflect macro headwinds, not legislative catalysts.

Full Analysis

1) What happened: On May 6, 2025, Sen. Britt (R-AL) introduced S.1630, the MOMS Act, in the 119th Congress. It was read twice and referred to the Senate HELP Committee. The bill directs HHS to launch a public website, pregnancy.gov, within one year of enactment, serving as a clearinghouse of resources for pregnant and postpartum women. The bill is at the earliest legislative stage with zero appropriations language. 2) Money trail: No authorized funding amount exists. The bill imposes a directive on HHS but does not allocate any specific dollars. Actual funding would require a separate appropriations bill, which has not been introduced. There is no contract vehicle, grant program, or tax credit in the text. 3) Structural winners and losers: No tickers are directly affected. The bill's requirement for a government website is too generic and too small to create measurable revenue for any public company. IT services firms like $ACN or $IBM could theoretically bid on web development, but with no funding authorized, any contract value is speculative and immaterial relative to their revenues. 4) Real market data: $ACN closed at $177.52 on 2026-04-30, down 10.47% in 30 days, with a 7-day decline of only 0.47%. $IBM closed at $228.08, down 5.91% in 30 days, with a 7-day drop of 1.69%. These moves align with broader tech weakness (IBM hit a 52-week low of $220.72) and show no correlation to a procedural bill from May 2025. 5) Timeline: The bill has been in committee since May 2025 with no further action in nearly 12 months. No hearings, markups, or floor votes have occurred. Passage probability is low for the remainder of the 119th Congress.

Intelligence Surface

Cross-referenced against federal contracts, SEC insider filings & congressional trade disclosures

Moderate

Some confirming evidence found across public data sources

Confirmed by:

Market Impact Score

1/10
Minimal ImpactModerateMajor Market Event

Related Presidential Actions

Executive orders & memoranda affecting the same sectors or companies

Exec OrderApr 30, 2026

Promoting Efficiency, Accountability, and Performance in Federal Contracting

This executive order mandates that federal agencies default to using fixed-price contracts for procurement, shifting away from cost-reimbursement models. It requires written justification and senior-level approval for any non-fixed-price contract over certain dollar thresholds (e.g., $10M for most agencies, $100M for the Department of War), and directs agencies to review and renegotiate their 10 largest non-fixed-price contracts within 90 days. The order also tasks OMB with implementation guidance and the Federal Acquisition Regulatory Council with proposing regulatory amendments within 120 days.

Exec OrderApr 18, 2026

Accelerating Medical Treatments for Serious Mental Illness

This executive order directs the FDA to prioritize review and facilitate 'Right to Try' access for psychedelic drugs, including ibogaine compounds, that have received Breakthrough Therapy designation for serious mental illnesses. It also allocates $50 million from HHS to support state programs advancing these treatments and mandates collaboration between HHS, FDA, VA, and the private sector to increase clinical trial participation and data sharing for these drugs. The Attorney General is further directed to expedite rescheduling reviews for approved Schedule I psychedelic substances.